|
Daily Medical Update
Cancer Screening: Prostate (PSA shared decision making)
Tuesday, February 24, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
The New England journal of medicine (2025) - Randomized Trial
Key Findings
- 23-year follow-up showed lower prostate-cancer mortality vs usual care in organized PSA screening programs.
- Absolute benefit increased over time, while overdiagnosis remained concentrated in low-risk disease.
📋 Practice Implication: For men 55-69, offer periodic PSA screening only via shared decision-making and emphasize long-horizon mortality benefit rather than short-term outcomes.
|
2. Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Can
Journal (2025) - Study
Key Findings
- At 9 years, Stockholm3 increased clinically significant cancer detection vs PSA-first testing and reduced unnecessary biopsies by >20%.
- Risk-stratified testing improved high-grade yield while decreasing benign/low-grade detections versus PSA alone.
📋 Practice Implication: When available, consider reflex Stockholm3-style risk stratification before biopsy referral to improve high-grade detection and reduce unnecessary procedures.
|
European urology (2026) - Randomized Trial
Key Findings
- In a randomized pathway, noncontrast MRI triage reduced biopsy referrals vs PSA-only workup.
- Detection of clinically significant cancer was non-inferior, while low-grade cancer detection decreased.
📋 Practice Implication: Use MRI-first triage in equivocal PSA cases to reduce low-value biopsies while preserving detection of clinically important disease.
|
4. Prostate-Specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the S
Journal (2025) - Study
Key Findings
- Using PSA density thresholds before MRI reduced MRI/biopsy utilization vs non-selective referral.
- Sensitivity for clinically significant cancer remained high with density cutoffs, with fewer negative procedures.
📋 Practice Implication: Incorporate PSA density thresholds into referral workflows to prioritize MRI/biopsy for men most likely to have clinically significant cancer.
|
5. Repeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging-gui
Journal (2025) - Study
Key Findings
- Repeat screening with blood-based risk prediction lowered repeat biopsy burden vs repeat PSA-alone strategies.
- Aggressive-cancer detection rates were preserved, improving screening efficiency over serial rounds.
📋 Practice Implication: For repeat-screening visits, risk-prediction blood tests can be used to defer low-value repeat biopsies in men with stable risk profiles.
|
European urology oncology (2025) - Randomized Trial
Key Findings
- Omitting routine systematic cores in MRI-positive pathways reduced total core number and procedure burden.
- This approach produced only a small drop in low-volume significant detections while reducing overdiagnosis.
📋 Practice Implication: For MRI-positive patients, avoid automatic systematic plus targeted cores in every case; use selective systematic sampling to limit overtesting.
|
JAMA network open (2025) - Meta-analysis
Key Findings
- Across randomized screening trials, cancer-specific mortality improved with screening, but all-cause/noncancer mortality remained neutral.
- These results showed no difference in all-cause mortality, supporting individualized counseling rather than one-size-fits-all screening.
📋 Practice Implication: Counsel patients that PSA programs reduce prostate-cancer death but do not clearly change all-cause mortality, clarifying realistic benefit expectations.
|
Urology practice (2026) - Randomized Trial
Key Findings
- A vulnerable-population RCT increased shared-decision quality scores and patient knowledge vs usual counseling.
- The intervention improved value-concordant PSA decisions without increasing decisional conflict.
📋 Practice Implication: Add structured literacy/shared-decision tools for lower-health-literacy populations to improve informed, preference-concordant screening choices.
|
|
Recent prostate-screening evidence supports risk-stratified pathways (PSA density, MRI-first, and multi-marker tests) that preserve detection of clinically significant disease while reducing unnecessary biopsies. Long-term trial follow-up continues to show organ-specific mortality benefit, reinforcing shared decision-making focused on benefit-harm tradeoffs. Primary care workflows should prioritize informed choice and targeted referral rather than blanket annual testing.
|
|